Medicine Supply Notification: Combisal®

  • Home
  • News
  • Medicine Supply Notification: Combisal®
Add to CPD Start a discussion

Combisal® (Fluticasone 125microgram / Salmeterol 25microgram) pressurised metered dose inhaler (pMDI).  The SSP will enable community pharmacists in England and Wales to supply patients with Fluticasone 125microgram/Salmeterol 25microgram pressurised metered dose inhaler (pMDI).

The SSP is now available to view on the NHS Business Service Authority (BSA)’s dedicated SSP web page, along with supporting guidance. The SSP came into effect on Friday, 22 July 2022 and is currently due to expire on Friday, 19 August 2022.  For any questions, please contact the NHS Prescription Service.

Update on Monday, 1 August 2022.

Twelve of the thirteen Serious Shortage Protocols (SSPs) covering Hormone Replacement Therapy (HRT) medicines are being extended.  These are SSP019, SSP020 and SSPs 022 to 031. In addition, the dose equivalence advice and endorsement guidance for SSPs 024 and 025 have been updated.

 The end date for these SSPs will now be 28 October 2022. SSP021 is not being extended and ended on 29 July 2022.

 Separately, endorsement guidance for SSP034 (Combisal®) has now been published.

If you have any questions regarding the SSPs, please contact the NHS Prescription Service via any method below:


Telephone: 0300 330 1349

Textphone: 18001 0300 330 1349

Expiry date: Aug 31st, 2022